Who Owns BridgeBio Oncology Therapeutics Stock?
NASDAQ: BBOTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 71.84%
- Held by insiders
- 27.10%
- Institutional holders
- 104
- Institutions 71.8%
- Insiders 27.1%
- Public and other 1.1%
Who owns BridgeBio Oncology Therapeutics stock?
Institutional investors own about 71.8% of BridgeBio Oncology Therapeutics's shares, spread across 104 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 27.10% of BBOT.
The largest institutional holders are Cormorant Asset Management, LP (22.28%), Blackrock Inc. (5.00%) and Omega Fund Management, Llc (4.10%). Together, the top 10 institutions control 54.2% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their BBOT positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of BBOT
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Cormorant Asset Management, LP | 17.88M | 22.28% | 0.0% |
| Blackrock Inc. | 4.01M | 5.00% | +86.2% |
| Omega Fund Management, Llc | 3.29M | 4.10% | 0.0% |
| Deerfield Management Company, L.P | 3.14M | 3.91% | -35.8% |
| Alphabet Inc. | 2.82M | 3.52% | 0.0% |
| Citadel Advisors Llc | 2.70M | 3.36% | +3.0% |
| Enavate Sciences Gp, LLC | 2.63M | 3.27% | 0.0% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2.51M | 3.13% | +100.0% |
| Armistice Capital, LLC | 2.26M | 2.82% | +28.3% |
| Novo Holdings A/S | 2.25M | 2.80% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of BBOT
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.42M | 1.77% |
| BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 883.05K | 1.10% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 658.48K | 0.82% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 539.58K | 0.67% |
| iShares Trust-iShares Biotechnology ETF | 373.33K | 0.47% |
| BlackRock Health Sciences Term Trust | 263.67K | 0.33% |
| SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF | 225.29K | 0.28% |
| T. Rowe Price Health Sciences Fund, Inc. | 222.51K | 0.28% |
| ROYCE MICRO-CAP TRUST, INC.-Royce Micro-Cap Trust Inc | 210.85K | 0.26% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 206.03K | 0.26% |
Frequently asked questions
Who is the largest shareholder of BridgeBio Oncology Therapeutics?
Cormorant Asset Management, LP is the largest institutional shareholder of BBOT, owning 22.28% of shares outstanding (17.88M shares) as of its latest 13F filing.
What percentage of BridgeBio Oncology Therapeutics is owned by institutions?
Institutions own about 71.8% of BBOT shares and 98.5% of the public float.
How much of BridgeBio Oncology Therapeutics do insiders own?
Insiders, such as officers and directors, own about 27.10% of BBOT shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.